Compare · BGLC vs CI
BGLC vs CI
Side-by-side comparison of BioNexus Gene Lab Corp (BGLC) and The Cigna Group (CI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BGLC and CI operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $76.60B, about 20985.7x BGLC ($3.7M).
- CI has hit the wire 9 times in the past 4 weeks while BGLC has been quiet.
- CI has more recent analyst coverage (25 ratings vs 0 for BGLC).
- Company
- BioNexus Gene Lab Corp
- The Cigna Group
- Price
- $1.54-21.83%
- $289.60+1.16%
- Market cap
- $3.7M
- $76.60B
- 1M return
- -28.04%
- -
- 1Y return
- -68.83%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest BGLC
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Regulation FD Disclosure, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development
- SEC Form 10-Q filed by BioNexus Gene Lab Corp
- SEC Form 10-K filed by BioNexus Gene Lab Corp
- SEC Form NT 10-K filed by BioNexus Gene Lab Corp
- BioNexus Gene Lab Corp filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman
- BioNexus Gene Lab Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest CI
- Cigna Healthcare Expands AI-Enabled Personalized Support to Help More Customers Access Care Earlier and Improve Affordability
- The Cigna Group Declares Quarterly Dividend
- New insider Holgerson Bryan claimed ownership of 7,693 shares (SEC Form 3)
- New insider Kautzner Adam claimed ownership of 13,533 shares (SEC Form 3)
- New insider Sadler Jason D claimed ownership of 34,705 shares (SEC Form 3)
- New insider Sanford Paul A claimed ownership of 4,073 shares (SEC Form 3)
- New insider Perlberg Matthew claimed ownership of 9,345 shares (SEC Form 3)
- The Cigna Group's Second Quarter 2026 Earnings Release Details
- Evernorth Launches Pharmacy Forward: A Simpler, Faster Specialty Pharmacy Experience for Patients Managing Complex Conditions
- The Cigna Group Foundation Honors David M. Cordani's Leadership with New Grant to Strengthen Military Communities